Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia-Reference-Cited by-同舟云学术

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia

Published:2022-12-30 Issue:2 Volume:43 Page:413-423
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Larrey Dominique¹,D'Erasmo Laura²,O'Brien Sallyann³,Arca Marcello²,Cefalù Angelo Baldassare,Di Costanzo Alessia,Bini Simone,Giammanco Antonina,Averna Maurizio,Iannuzzo Gabriella,Fortunato Giuliana,Gentile Marco,Di Taranto Maria Donata,Pujia Arturo,Montalcini Tiziana,Pavanello Chiara,Calabresi Laura,Vigna Giovanni Battista,Bucci Marco,Bonomo Katia,Sampietro Tiziana,Sbrana Francesco,Suppressa Patrizia,Sabbà Carlo,Fimiani Fabio,Cesaro Arturo,Calabrò Paolo,Ventura Fulvio,D’Addato Sergio,Pisciotta Livia,Bertolini Stefano,

Affiliation:

1. University Hospital of Montpellier Montpellier France

2. Department of Translational and Precision Medicine ‘Sapienza’ University Rome Italy

3. Amryt Pharmaceuticals DAC Dublin Ireland

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15497

Reference60 articles.

1. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study